Patient with history of atrial fibrillation: 1 trials - CAPRAF (Tveit)
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Vascular death | no data | | atrial fibrillation recurrence | no data | | more than one AF recurrence | no data | | Vascular events | no data | | hospitalisation for heart failure | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients without history of AF (primary prevention): 1 trials - CHARM (AF ancillary study)
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| atrial fibrillation | 0.82 [0.67 1.01] | p=1.00 | 0 | 6446 | 1 | CHARM (AF ancillary study), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Unprotected left main artery stenosis: 1 trials - SYNTAX (unprotected left main sub group)
| DES vs CABG | No demonstrated result suggested target-vessel revascularization by 45% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| 2 yr Death (all cause) | no data | | myocardial infarction (fatal and non fatal) | 1.00 [0.45 2.22] | p=1.00 | 0 | 614 | 1 | SYNTAX (unprotected left main sub group), | | 4 yr mortality from all causes | no data | | cardiac death | no data | | 4 yr MI | no data | | 4 yr death or MI | no data | | MACE | 0.76 [0.17 3.48] | p=1.00 | 0 | 614 | 1 | SYNTAX (unprotected left main sub group), | | 2 yr MACE | no data | | target-vessel revascularization | 0.55 [0.32 0.95] | p=0.04 | 0 | 614 | 1 | SYNTAX (unprotected left main sub group), | | 2 yr TLR | no data | | 4 yr TLR | no data | | target lesion revascularisation | no data | | CABG | no data | | in-lesion binary restenosis | no data | | angiographic restenosis | no data | | All cause death | 1.00 [0.45 2.22] | p=1.00 | 0 | 614 | 1 | SYNTAX (unprotected left main sub group), | | Stent thrombosis (any, end of follow up) | no data | | 4y stent thrombosis (ARC) | no data | | 4 yr stent thrombosis | no data | | Acute stent thrombosis (<=24h) | no data | | sub acute stent thrombosis (1-30 days) | no data | | late stent thrombosis (31days - 1year) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with or without hypertension: 1 trials - SCOPE (diabetic subgroup)
| candesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.82 [0.53 1.27] | p=1.00 | 0 | 599 | 1 | SCOPE (diabetic subgroup), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.91 [0.46 1.83] | p=1.00 | 0 | 599 | 1 | SCOPE (diabetic subgroup), | | microvascular events | no data | | Non fatal MI | no data | | All cause death | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 8 trials - ARCH-J - CHARM-Added - CHARM-Alternative - Mitrovic et al. - RESOLVD (candesartan alone) - RESOLVD association - SPICE - STRETCH
| candesartan vs enalapril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | 1.83 [0.90 3.74] | p=1.00 | 0 | 436 | 1 | RESOLVD (candesartan alone), | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | 2.05 [0.89 4.70] | p=1.00 | 0 | 436 | 1 | RESOLVD (candesartan alone), | | Hospitalization for any reason | 1.21 [0.72 2.02] | p=1.00 | 0 | 436 | 1 | RESOLVD (candesartan alone), | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | 1.00 [0.10 9.71] | p=1.00 | 0 | 436 | 1 | RESOLVD (candesartan alone), | | angiodema | no data | | Adverse events | no data | | All cause death | 1.67 [0.56 4.99] | p=1.00 | 0 | 436 | 1 | RESOLVD (candesartan alone), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs placebo | No demonstrated result by 130% (harmful effect) Hyperkalaemia by 535% (harmful effect) Hypotension by 130% (harmful effect) suggested Cardiovascular death or hospital admission for CHF by 18% (not demonstrated) suggested hospitalisation for heart failure by 28% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | 0.86 [0.72 1.02] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | Cardiovascular death or hospital admission for CHF | 0.82 [0.69 0.99] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | death or cardiovascular hospitalization | no data | | Cardiovascular death | 0.87 [0.71 1.06] | p=1.00 | 0 | 2246 | 2 | CHARM-Alternative, Mitrovic et al., | | hospitalisation for heart failure | 0.72 [0.59 0.88] | p=0.04 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | Hospitalization for any reason | 0.93 [0.78 1.11] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | 2.30 [1.45 3.65] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | Hyperkalaemia | 6.35 [1.87 21.51] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | Cough | 0.98 [0.59 1.64] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | Hypotension | 2.30 [1.20 4.42] | p=0.04 | 0 | 2246 | 2 | CHARM-Alternative, Mitrovic et al., | | angiodema | 3.01 [0.12 73.88] | p=1.00 | 0 | 2028 | 1 | CHARM-Alternative, | | Adverse events | 0.96 [0.79 1.18] | p=1.00 | 0 | 2464 | 3 | CHARM-Alternative, Mitrovic et al., Mitrovic et al., | | All cause death | 0.90 [0.75 1.09] | p=1.00 | 0 | 3652 | 5 | ARCH-J, CHARM-Alternative, Mitrovic et al.,SPICE, STRETCH, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result by 91% (harmful effect) Hyperkalaemia by 387% (harmful effect) Adverse events by 32% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | 0.95 [0.81 1.10] | p=1.00 | 0 | 2989 | 2 | CHARM-Added, RESOLVD association, | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | 0.88 [0.74 1.05] | p=1.00 | 0 | 2989 | 2 | CHARM-Added, RESOLVD association, | | Hospitalization for any reason | 1.00 [0.85 1.17] | p=1.00 | 0 | 2989 | 2 | CHARM-Added, RESOLVD association, | | 1.91 [1.36 2.69] | p=0.04 | 0 | 2989 | 2 | CHARM-Added, RESOLVD association, | | Hyperkalaemia | 4.87 [2.37 10.03] | p=0.04 | 0 | 2548 | 1 | CHARM-Added, | | Cough | no data | | Hypotension | 1.45 [0.96 2.18] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | angiodema | 0.66 [0.11 3.98] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | Adverse events | 1.32 [1.15 1.51] | p=0.04 | 0 | 5096 | 2 | CHARM-Added, CHARM-Added, | | All cause death | 0.93 [0.79 1.10] | p=1.00 | 0 | 2989 | 2 | CHARM-Added, RESOLVD association, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients already receiving ACE inhibitor: 1 trials - CHARM-Added
| candesartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result by 92% (harmful effect) Hyperkalaemia by 387% (harmful effect) Adverse events by 32% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | 0.92 [0.78 1.07] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | 0.87 [0.72 1.03] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | Hospitalization for any reason | 0.99 [0.84 1.17] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | 1.92 [1.36 2.71] | p=0.04 | 0 | 2548 | 1 | CHARM-Added, | | Hyperkalaemia | 4.87 [2.37 10.03] | p=0.04 | 0 | 2548 | 1 | CHARM-Added, | | Cough | no data | | Hypotension | 1.45 [0.96 2.18] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | angiodema | 0.66 [0.11 3.98] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, | | Adverse events | 1.32 [1.15 1.51] | p=0.04 | 0 | 5096 | 2 | CHARM-Added, CHARM-Added, | | All cause death | 0.91 [0.77 1.08] | p=1.00 | 0 | 2548 | 1 | CHARM-Added, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients intolerant to ACE inhibitors: 2 trials - CHARM-Alternative - SPICE
| candesartan vs placebo | No demonstrated result by 130% (harmful effect) Hyperkalaemia by 535% (harmful effect) Hypotension by 312% (harmful effect) suggested Cardiovascular death or hospital admission for CHF by 18% (not demonstrated) suggested hospitalisation for heart failure by 28% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | 0.86 [0.72 1.02] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | Cardiovascular death or hospital admission for CHF | 0.82 [0.69 0.99] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | death or cardiovascular hospitalization | no data | | Cardiovascular death | 0.87 [0.71 1.07] | p=1.00 | 0 | 2028 | 1 | CHARM-Alternative, | | hospitalisation for heart failure | 0.72 [0.59 0.88] | p=0.04 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | Hospitalization for any reason | 0.93 [0.78 1.11] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | 2.30 [1.45 3.65] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | Hyperkalaemia | 6.35 [1.87 21.51] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | Cough | 0.98 [0.59 1.64] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, | | Hypotension | 4.12 [1.98 8.58] | p=0.04 | 0 | 2028 | 1 | CHARM-Alternative, | | angiodema | 3.01 [0.12 73.88] | p=1.00 | 0 | 2028 | 1 | CHARM-Alternative, | | Adverse events | 1.11 [0.90 1.38] | p=1.00 | 0 | 2028 | 1 | CHARM-Alternative, | | All cause death | 0.90 [0.74 1.09] | p=1.00 | 0 | 2298 | 2 | CHARM-Alternative,SPICE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients previously untreated with ACE inhibitors: 1 trials - ARCH-J
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 0.65 [0.11 3.94] | p=1.00 | 0 | 292 | 1 | ARCH-J, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with preserved-LVEF heart failure : 1 trials - CHARM preserved
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - CHARM preserved
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All diseases requiring ACEi (HF, CHD, HT,...): 8 trials - SCOPE - HIJ-CREATE - CASE-J - ALPINE - E-COST - E-COST-R - HIJ-CREATE - Takahashi
| candesartan vs amlodipine | No demonstrated result suggested Diabetes onset by 36% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.94 [0.48 1.83] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | stroke (fatal and non fatal) | 1.27 [0.87 1.87] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 1.25 [0.64 2.41] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | All cause death | 0.85 [0.62 1.16] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.64 [0.42 0.97] | p=0.04 | 0 | 4703 | 1 | CASE-J, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.39 [0.12 1.26] | p=1.00 | 0 | 80 | 1 | Takahashi, | | All cause death | 0.06 [0.00 1.04] | p=1.00 | 0 | 80 | 1 | Takahashi, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs conventional treatment | No demonstrated result suggested stroke (fatal and non fatal) by 27% (not demonstrated) suggested Diabetes onset by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.14 [0.69 1.88] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | myocardial infarction (fatal and non fatal) | 0.84 [0.55 1.28] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | stroke (fatal and non fatal) | 0.73 [0.56 0.95] | p=0.04 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.83 [0.62 1.12] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | All cause death | 1.15 [0.82 1.61] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.39 [0.16 0.94] | p=0.04 | 0 | 2049 | 1 | HIJ-CREATE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Cardiovascular death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | myocardial infarction (fatal and non fatal) | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | stroke (fatal and non fatal) | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Coronary event | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | cardiac death | no data | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.12 [0.02 1.00] | p=1.00 | 0 | 393 | 1 | ALPINE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.90 [0.75 1.08] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Cardiovascular death | 0.95 [0.75 1.20] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | myocardial infarction (fatal and non fatal) | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | stroke (fatal and non fatal) | 0.77 [0.58 1.02] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Coronary event | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cardiac death | 0.99 [0.52 1.91] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.97 [0.81 1.16] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | 1.08 [0.87 1.33] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Diabetes onset | 0.80 [0.62 1.04] | p=1.00 | 0 | 4937 | 1 | SCOPE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| Candesartan vs usual care | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 8 trials - HSCS - SCOPE - CASE-J - ALPINE - E-COST - E-COST-R - HIJ-CREATE - Takahashi
| candesartan vs amlodipine | No demonstrated result suggested Diabetes onset by 36% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.94 [0.48 1.83] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | stroke (fatal and non fatal) | 1.27 [0.87 1.87] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 1.25 [0.64 2.41] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | All cause death | 0.85 [0.62 1.16] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.64 [0.42 0.97] | p=0.04 | 0 | 4703 | 1 | CASE-J, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.39 [0.12 1.26] | p=1.00 | 0 | 80 | 1 | Takahashi, | | All cause death | 0.06 [0.00 1.04] | p=1.00 | 0 | 80 | 1 | Takahashi, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs conventional treatment | No demonstrated result suggested stroke (fatal and non fatal) by 27% (not demonstrated) suggested Diabetes onset by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.14 [0.69 1.88] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | myocardial infarction (fatal and non fatal) | 0.84 [0.55 1.28] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | stroke (fatal and non fatal) | 0.73 [0.56 0.95] | p=0.04 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.83 [0.62 1.12] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | All cause death | 1.15 [0.82 1.61] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.39 [0.16 0.94] | p=0.04 | 0 | 2049 | 1 | HIJ-CREATE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Cardiovascular death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | myocardial infarction (fatal and non fatal) | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | stroke (fatal and non fatal) | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Coronary event | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | cardiac death | no data | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.12 [0.02 1.00] | p=1.00 | 0 | 393 | 1 | ALPINE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.90 [0.75 1.08] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Cardiovascular death | 0.95 [0.75 1.20] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | myocardial infarction (fatal and non fatal) | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | stroke (fatal and non fatal) | 0.77 [0.58 1.02] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Coronary event | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cardiac death | 0.99 [0.52 1.91] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.97 [0.81 1.16] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | 1.08 [0.87 1.33] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Diabetes onset | 0.80 [0.62 1.04] | p=1.00 | 0 | 4937 | 1 | SCOPE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| deserpidine +methylclothiazide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.73 [0.46 1.13] | p=1.00 | 0 | 452 | 1 | HSCS, | | Cardiovascular death | 0.74 [0.37 1.50] | p=1.00 | 0 | 452 | 1 | HSCS, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.83 [0.51 1.35] | p=1.00 | 0 | 452 | 1 | HSCS, | | Coronary event | 0.94 [0.30 2.96] | p=1.00 | 0 | 452 | 1 | HSCS, | | Heart failure | 0.07 [0.00 1.29] | p=1.00 | 0 | 452 | 1 | HSCS, | | All cause death | 1.02 [0.57 1.83] | p=1.00 | 0 | 452 | 1 | HSCS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Nephropathy: 2 trials - E-COST-R - Takahashi
| candesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.39 [0.12 1.26] | p=1.00 | 0 | 80 | 1 | Takahashi, | | All cause death | 0.06 [0.00 1.04] | p=1.00 | 0 | 80 | 1 | Takahashi, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs conventional treatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.04 [0.25 4.35] | p=1.00 | 0 | 141 | 1 | E-COST-R, | | myocardial infarction (fatal and non fatal) | 2.09 [0.37 11.78] | p=1.00 | 0 | 141 | 1 | E-COST-R, | | stroke (fatal and non fatal) | 0.89 [0.42 1.88] | p=1.00 | 0 | 141 | 1 | E-COST-R, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.68 [0.29 1.57] | p=1.00 | 0 | 141 | 1 | E-COST-R, | | All cause death | 1.04 [0.25 4.35] | p=1.00 | 0 | 141 | 1 | E-COST-R, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients undergoing dialysis : 2 trials - Takahashi et al - Suzuki et al
| candesartan vs usual care | No demonstrated result suggested cardiovascular events by 47% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.53 [0.34 0.82] | p=0.04 | 0 | 446 | 2 | Takahashi et al,Suzuki et al, | | Cardiovascular death | 0.60 [0.28 1.27] | p=1.00 | 0 | 366 | 1 | Suzuki et al, | | All cause death | 0.60 [0.35 1.04] | p=1.00 | 0 | 446 | 2 | Takahashi et al,Suzuki et al, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 1 trials - CASE-J
| candesartan vs amlodipine | No demonstrated result suggested Diabetes onset by 36% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.94 [0.48 1.83] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | stroke (fatal and non fatal) | 1.27 [0.87 1.87] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 1.25 [0.64 2.41] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | All cause death | 0.85 [0.62 1.16] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.64 [0.42 0.97] | p=0.04 | 0 | 4703 | 1 | CASE-J, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with cardiovascular disease: 1 trials - HIJ-CREATE
| candesartan vs conventional treatment | No demonstrated result suggested Diabetes onset by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.12 [0.65 1.94] | p=1.00 | 0 | 2049 | 1 | HIJ-CREATE, | | myocardial infarction (fatal and non fatal) | 1.12 [0.65 1.91] | p=1.00 | 0 | 2049 | 1 | HIJ-CREATE, | | stroke (fatal and non fatal) | 0.92 [0.61 1.39] | p=1.00 | 0 | 2049 | 1 | HIJ-CREATE, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.91 [0.59 1.41] | p=1.00 | 0 | 2049 | 1 | HIJ-CREATE, | | All cause death | 1.17 [0.82 1.68] | p=1.00 | 0 | 2049 | 1 | HIJ-CREATE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.39 [0.16 0.94] | p=0.04 | 0 | 2049 | 1 | HIJ-CREATE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Post stroke: 1 trials - HSCS
| deserpidine +methylclothiazide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.73 [0.46 1.13] | p=1.00 | 0 | 452 | 1 | HSCS, | | Cardiovascular death | 0.74 [0.37 1.50] | p=1.00 | 0 | 452 | 1 | HSCS, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.83 [0.51 1.35] | p=1.00 | 0 | 452 | 1 | HSCS, | | Coronary event | 0.94 [0.30 2.96] | p=1.00 | 0 | 452 | 1 | HSCS, | | Heart failure | 0.07 [0.00 1.29] | p=1.00 | 0 | 452 | 1 | HSCS, | | All cause death | 1.02 [0.57 1.83] | p=1.00 | 0 | 452 | 1 | HSCS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Subjects with pre-hypertension: 1 trials - TROPHY
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| hypertension | 0.84 [0.63 1.13] | p=1.00 | 0 | 772 | 1 | TROPHY, | | Serious adverse event | 0.60 [0.30 1.19] | p=1.00 | 0 | 787 | 1 | TROPHY, | | cardiovascular events | 0.16 [0.02 1.37] | p=1.00 | 0 | 787 | 1 | TROPHY, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Uncomplicated hypertension: 2 trials - ALPINE - E-COST
| candesartan vs conventional treatment | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 59% (not demonstrated) suggested stroke (fatal and non fatal) by 42% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 2.83 [0.12 69.67] | p=1.00 | 0 | 2048 | 1 | E-COST, | | myocardial infarction (fatal and non fatal) | 0.41 [0.19 0.87] | p=0.04 | 0 | 2048 | 1 | E-COST, | | stroke (fatal and non fatal) | 0.58 [0.40 0.84] | p=0.04 | 0 | 2048 | 1 | E-COST, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.81 [0.51 1.28] | p=1.00 | 0 | 2048 | 1 | E-COST, | | All cause death | 0.94 [0.24 3.79] | p=1.00 | 0 | 2048 | 1 | E-COST, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Cardiovascular death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | myocardial infarction (fatal and non fatal) | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | stroke (fatal and non fatal) | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Coronary event | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | cardiac death | no data | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.12 [0.02 1.00] | p=1.00 | 0 | 393 | 1 | ALPINE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 8 trials - SCOPE - TROPHY - CASE-J - ALPINE - E-COST - E-COST-R - HIJ-CREATE - Takahashi
| candesartan vs amlodipine | No demonstrated result suggested Diabetes onset by 36% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.94 [0.48 1.83] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | stroke (fatal and non fatal) | 1.27 [0.87 1.87] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 1.25 [0.64 2.41] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | All cause death | 0.85 [0.62 1.16] | p=1.00 | 0 | 4703 | 1 | CASE-J, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.64 [0.42 0.97] | p=0.04 | 0 | 4703 | 1 | CASE-J, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.39 [0.12 1.26] | p=1.00 | 0 | 80 | 1 | Takahashi, | | All cause death | 0.06 [0.00 1.04] | p=1.00 | 0 | 80 | 1 | Takahashi, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs conventional treatment | No demonstrated result suggested stroke (fatal and non fatal) by 27% (not demonstrated) suggested Diabetes onset by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.14 [0.69 1.88] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | myocardial infarction (fatal and non fatal) | 0.84 [0.55 1.28] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | stroke (fatal and non fatal) | 0.73 [0.56 0.95] | p=0.04 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | Coronary event | no data | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.83 [0.62 1.12] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | All cause death | 1.15 [0.82 1.61] | p=1.00 | 0 | 4238 | 3 | E-COST,E-COST-R,HIJ-CREATE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.39 [0.16 0.94] | p=0.04 | 0 | 2049 | 1 | HIJ-CREATE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Cardiovascular death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | myocardial infarction (fatal and non fatal) | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | stroke (fatal and non fatal) | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | Coronary event | 0.99 [0.06 16.02] | p=1.00 | 0 | 393 | 1 | ALPINE, | | cardiac death | no data | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.99 [0.02 50.40] | p=1.00 | 0 | 393 | 1 | ALPINE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | 0.12 [0.02 1.00] | p=1.00 | 0 | 393 | 1 | ALPINE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.89 [0.74 1.06] | p=1.00 | 0 | 5724 | 2 | SCOPE,TROPHY, | | Cardiovascular death | 0.95 [0.75 1.20] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | myocardial infarction (fatal and non fatal) | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | stroke (fatal and non fatal) | 0.77 [0.58 1.02] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Coronary event | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cardiac death | 0.99 [0.52 1.91] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cancer related death | no data | | Heart failure | no data | | hypertension | 0.84 [0.63 1.13] | p=1.00 | 0 | 772 | 1 | TROPHY, | | All cause death | 0.97 [0.81 1.16] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | 1.08 [0.87 1.33] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Serious adverse event | 0.60 [0.30 1.19] | p=1.00 | 0 | 787 | 1 | TROPHY, | | cardiovascular events | 0.89 [0.74 1.06] | p=1.00 | 0 | 5724 | 2 | SCOPE,TROPHY, | | Diabetes onset | 0.80 [0.62 1.04] | p=1.00 | 0 | 4937 | 1 | SCOPE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - SCOPE
| candesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.90 [0.75 1.08] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Cardiovascular death | 0.95 [0.75 1.20] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | myocardial infarction (fatal and non fatal) | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | stroke (fatal and non fatal) | 0.77 [0.58 1.02] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Coronary event | 1.10 [0.78 1.56] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cardiac death | 0.99 [0.52 1.91] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | cancer related death | no data | | Heart failure | no data | | All cause death | 0.97 [0.81 1.16] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | 1.08 [0.87 1.33] | p=1.00 | 0 | 4937 | 1 | SCOPE, | | Diabetes onset | 0.80 [0.62 1.04] | p=1.00 | 0 | 4937 | 1 | SCOPE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Tebbe
| desmoteplase vs alteplase | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| recurrence of pulmonary embolism | no data | | All cause death | no data | | Minor bleeding | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Superficial thrombophlebitis of the leg : 2 trials - Andreozzi (200 vs 100) - Andreozzi (desmin SC vs 100)
| desmin 200 vs desmin 100 | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deep vein thrombosis | no data | | Venous thromboembolism end of treatment | no data | | Venous thromboembolism | no data | | Pain disappearance | no data | | Major bleeding | no data | | Extension and/or recurrence of SVT | no data | | Heparin-induced thrombocytopenia | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| desmin SC vs desmin 100 | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deep vein thrombosis | no data | | Venous thromboembolism end of treatment | no data | | Venous thromboembolism | no data | | Pain disappearance | no data | | Major bleeding | no data | | Extension and/or recurrence of SVT | no data | | Heparin-induced thrombocytopenia | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Elective hip replacement: 3 trials - Ericksson - REVASC - Eriksson
| desirudin vs enoxaparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| desirudin vs UFH | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Orthopedic surgery: 3 trials - Ericksson - REVASC - Eriksson
| desirudin vs enoxaparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| desirudin vs UFH | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
